Part VI: Summary of the risk management plan for Glucofarm Once

This is a summary of the risk management plan (RMP) for Glucofarm Once. The RMP details important risks of Glucofarm Once how these risks can be minimised, and how more information will be obtained about Glucofarm Once's risks and uncertainties (missing information).

Glucofarm Once's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Glucofarm Once should be used.

I. The medicine and what it is used for

Glucofarm Once is authorised for relief of symptoms in mild to moderate osteoarthritis (see SmPC for the full indication). It contains glucosamine as the active substances and it is given orally as film-coated tablets.

II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of Glucofarm Once, together with measures to minimise such risks and the proposed studies for learning more about Glucofarm Once's risks, are outlined below.

- Product information including warnings, precautions, and advice on correct use. Package leaflet is enclosed in the package and the Summary of Product Characteristics (and Package Leaflet) are published on the webpage of the Danish Medicines Agency.

Together, these measures constitute *routine risk minimisation* measures.

If important information that may affect the safe use of Glucofarm Once is not yet available, it is listed under 'missing information' below.

II.A List of important risks and missing information

Important risks of Glucofarm Once are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely taken. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Glucofarm Once. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine);

Summary of safety concerns	
Important identified risks	None
Important potential risks	None
Missing information	None

II.B Summary of important risks

The safety information in the proposed Product Information is aligned to the reference medicinal product.

II.C Post-authorisation development plan

II.C.1 Studies which are conditions of the marketing authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of Glucofarm Once.

II.C.2 Other studies in post-authorisation development plan

There are no studies required for Glucofarm Once.